visipaque 652 mg/1 ml otopina za injekciju
amicus pharma d.o.o. - jodiksanol - otopina za injekciju - 652 mg/1 ml - 1 ml otopine za injekciju sadrži: 652 mg jodiksanola, što odgovara 320 mg joda
visipaque 652 mg/1 ml otopina za injekciju
amicus pharma d.o.o. - jodiksanol - otopina za injekciju - 652 mg/1 ml - 1 ml otopine za injekciju sadrži: 652 mg jodiksanola, što odgovara 320 mg joda
visipaque 652 mg/1 ml otopina za injekciju
amicus pharma d.o.o. - jodiksanol - otopina za injekciju - 652 mg/1 ml - 1 ml otopine za injekciju sadrži: 652 mg jodiksanola, što odgovara 320 mg joda
biemexol 647 mg/1 ml otopina za injekciju
intrade pharm d.o.o - joheksol - otopina za injekciju - 647 mg/1 ml - 1 ml otopine za injekciju sadrži: 647 mg joheksola (što odgovara 300 mg joda)
biemexol 647 mg/1 ml otopina za injekciju
intrade pharm d.o.o - joheksol - otopina za injekciju - 647 mg/1 ml - 1 ml otopine za injekciju sadrži: 647 mg joheksola (što odgovara 300 mg joda)
biemexol 755 mg/1 ml otopina za injekciju
intrade pharm d.o.o - joheksol - otopina za injekciju - 755 mg/1 ml - 1 ml otopine za injekciju sadrži: 755 mg joheksola (što odgovara 350 mg joda)
biemexol 755 mg/1 ml otopina za injekciju
intrade pharm d.o.o - joheksol - otopina za injekciju - 755 mg/1 ml - 1 ml otopine za injekciju sadrži: 755 mg joheksola (što odgovara 350 mg joda)
tecartus
kite pharma eu b.v. - autologous peripheral blood t cells cd4 and cd8 selected and cd3 and cd28 activated transduced with retroviral vector expressing anti-cd19 cd28/cd3-zeta chimeric antigen receptor and cultured (brexucabtagene autoleucel) - limfom, mantel-stanica - antineoplastična sredstva - mantle cell lymphomatecartus is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (mcl) after two or more lines of systemic therapy including a bruton’s tyrosine kinase (btk) inhibitor. acute lymphoblastic leukaemiatecartus is indicated for the treatment of adult patients 26 years of age and above with relapsed or refractory b-cell precursor acute lymphoblastic leukaemia (all).
breyanzi
bristol-myers squibb pharma eeig - cd19-directed genetically modified autologous cell-based product consisting of purified cd8+ t-cells (cd8+ cells), cd19-directed genetically modified autologous cell-based product consisting of purified cd4+ t cells (cd4+ cells) - lymphoma, large b-cell, diffuse; lymphoma, follicular; mediastinal neoplasms - antineoplastična sredstva - breyanzi is indicated for the treatment of adult patients with diffuse large b-cell lymphoma (dlbcl), high grade b-cell lymphoma (hgbcl), primary mediastinal large b-cell lymphoma (pmbcl) and follicular lymphoma grade 3b (fl3b), who relapsed within 12 months from completion of, or are refractory to, first-line chemoimmunotherapy.
humalog
eli lilly nederland b.v. - inzulin lispro - Šećerna bolest - lijekovi koji se koriste u dijabetesu - za liječenje odraslih i djece s dijabetesom koji zahtijevaju inzulin za održavanje normalne homeostaze glukoze. humalog je također indiciran za početnu stabilizaciju šećerne bolesti.